ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP22-20 Pharmacy Benefit Exclusion for Tepezza TM
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါဖ့ၤဘြူၤအါရံၤ 12, 2020
တၢ်ဃုသ့ၣ်ညါတၢ်အစၢ
တၢ်ပာ်ဖျါ 1611 - 1620 လၢ 4179 အစၢတဖၣ်အကျါ
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP16-20 Pharmacy Benefit Exclusion for Padcev TM and Enhertu ®
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါဖ့ၤဘြူၤအါရံၤ 12, 2020
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP21-20 Pharmacy Benefit Update – New Drug-Related Prior Authorization (PA) with Quantity Limit (QL) Criteria: Baclofen
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါဖ့ၤဘြူၤအါရံၤ 12, 2020
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP18-20 Pharmacy Benefit Exclusion for Calcipotriene-Betamethasone Dipropionate Suspension 0.005-0.064% (authorized generic (AG) of Taclonex suspension)
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါဖ့ၤဘြူၤအါရံၤ 12, 2020
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P9-20 MHCP Prenatal Service Third Party Liability Change
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါဖ့ၤဘြူၤအါရံၤ 03, 2020
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P12-20 Updated Minnesota Health Care Programs and Minnesota Senior Health Options (MSHO) Prior Authorization and Medical Policy Requirements
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါဖ့ၤဘြူၤအါရံၤ 03, 2020
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P10-20 New Medical, Medical Drug and Behavioral Health Policy Management Updates – Effective April 6, 2020
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါဖ့ၤဘြူၤအါရံၤ 03, 2020
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P13-20 Medical Oncology Drug Prior Authorization Updates for Fully Insured Commercial and Medicare Advantage Subscribers- eviCore Healthcare Utilization Management (UM) Program
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါဖ့ၤဘြူၤအါရံၤ 03, 2020
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P11-20 Updated Bulletin: Commercial Inpatient Admission Notification Process Changes
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါဖ့ၤဘြူၤအါရံၤ 03, 2020
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
2020 February Bulletins
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါဖ့ၤဘြူၤအါရံၤ 03, 2020